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in Acute Myocardial Infarction?*
Christopher B. Granger, MD,y Thomas J. Povsic, MD, PHDzB lood biomarkers play a critical role in thedeﬁnition (1), prognostication (2,3), and de-cision making regarding management of
acute coronary syndromes (ACS). The most important
biomarker is troponin, which has evolved as the
foundation of diagnosis for acute myocardial infarc-
tion (AMI) (1) and, in its high-sensitivity fourth-gen-
eration iteration, plays an even more important role
in the evaluation of chest pain (4). Elevated cardiac
biomarkers are an important indicator of risk in clin-
ically validated models, such as the GRACE (Global
Registry of Acute Coronary Events) and TIMI (Throm-
bolysis In Myocardial Infarction) risk scores, whose
use is recommended by international guidelines (5).
However, clinicians do not routinely use these
models in practice, partly because we lack compelling
evidence that their use improves care.
Beyond troponin, other biomarkers ﬁgure selec-
tively in clinical care. Creatinine, measured routinely
for other reasons, is an important marker of risk for
ischemic events. And although signiﬁcantly impaired
renal function indicates higher risk for ischemic
cardiac events that would warrant aggressive man-
agement, it also identiﬁes risk of contrast nephro-
pathy that increases the threshold for coronary
angiography. Natriuretic peptides also indicate risk,
particularly for both short- and long-term mortality
(6,7), whereas C-reactive protein elevation predicts
longer-term mortality (8).*Editorials published in the Journal of the American College of Cardiology
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specialized blood biomarkers are associated with risk
following ACS, including 2 recent examples: mid-
regional pro-adrenomedullin and mid-regional pro-
atrial natriuretic peptide (9). Although frequently
predictive of events, these newer biomarkers have
not yet been shown to be of sufﬁcient value to add
meaningfully to available risk markers or utility to
clinical decisions.
The process of new marker development has been
well articulated (10). Even biomarkers like copeptin
(11) and growth differentiation factor 15 (12), both
strong predictors of risk and well-validated, have not
been incorporated into routine clinical care. Whereas
standard biomarkers such as troponin are important
for predicting risk, they must be considered in con-
text. Some patients with low levels of troponin are at
high risk whereas others with high levels of troponin
are at low risk, depending on clinical factors (13). This
highlights the need for accurate risk stratiﬁcation
using multivariable models, including clinical and
biomarker parameters, and clinical judgment.
Another underappreciated issue: the dynamic
nature of risk assessment. Whereas most studies have
evaluated the independent association of biomarker
levels assessed at the time of presentation, predictive
value varies over time (14). Thus, depending on the
intended use of biomarker information, time-updated
modeling may be important.
CATEGORIES OF BIOMARKERS. Biomarkers in ACS
have been categorized as markers of myocardial
necrosis, hemodynamic stress, inﬂammation, vascular
damage, and accelerated atherosclerosis (15). In this
way, information is generated regarding associated
pathways and/or consequences of the disease, which
may be helpful to understand the disease process
and identify potential therapeutic targets. For in-
stance, darapladib was developed as a lipoprotein-
associated phospholipase A2 inhibitor on the basis of
TABLE 1 Status of Development of Pro-Substance P as a Clinical Biomarker
Key Biomarker Metrics Accomplished
Robust assay Uncertain
Associated with risk Yes
Adds statistically signiﬁcant information to standard prediction Yes
Adds to standard prediction plus available biomarkers Marginally
Improves discrimination (C-index) Marginally
Validated in multiple cohorts No
Adds enough information to change managements No
Use to guide therapy improves clinical outcomes No
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1709(in large part) the robust independent association of
this marker with risk of vascular disease outcomes (16)
and evidence of a pathophysiologic role. However,
although theremay have been some effect on reducing
risk of AMI, large trials have not shown substantial
effects on clinical outcomes (17). This reminds us that
despite a strong relationship of a biomarker with a
disease and outcomes, we cannot accurately predict
that targeting thepathwaywill result in clinical beneﬁt.
NOVEL BIOMARKERS: HOW MAY THEY BE USEFUL?
There will continue to be discoveries of new bio-
markers that relate to AMI and subsequent risk, but few
of thesewillmake it into clinical use. In this issue of the
Journal, Ng et al. (18) studied pro-substance P, a more
stablemarker of substance P activity, evaluating its use
as a biomarker for risk following AMI. The cohort they
studied is robust, including 1,148 patients with 140
deaths, 112 heart failure hospitalizations, and 149
reinfarctions. After using the GRACE score, pro-
substance P was a strong independent predictor of
longer-term outcomes, especially for reclassifying pa-
tients at the low end of the risk scale.SEE PAGE 1698Pro-substance P relates to the labile substance P,
part of the tachykinin pathway, that acts primarily in
central and peripheral nerve tissue. Although it has
effects that might be viewed as beneﬁcial in AMI
(vasodilation and negative chronotropy), most are
likely harmful, as it is both pro-inﬂammatory and
pro-thrombotic. Nonetheless, the contribution of
substance P-signaling to the prothrombotic milieu of
AMI, compared with numerous other factors, remains
uncertain. The work of Ng et al. (18) supports the need
for research into the pathophysiologic role of sub-
stance P in ACS.
This study’s strengths are identifying a novel
biomarker that could lead to a more complete un-
derstanding of disease mechanisms and demon-
strating that pro-substance P adds to predictive
capability using various statistical techniques. The
weaknesses include the single-center nature of the
study and, most importantly, the lack of an inde-
pendent validation cohort, which is critical to conﬁrm
that the results are credible. In the decision tree
analysis, for example, it would be important to deﬁne
how pro-substance P contributes to risk assessmentafter, not before, use of the GRACE score and N-ter-
minal pro-B-type natriuretic peptide levels. Given
that the patients studied all had positive cardiac
biomarkers, and thus warrant aggressive therapy, it is
unclear to what degree elevated pro-substance P
levels would change treatment, as even patients with
low levels are at substantial risk of major adverse
cardiac events (>9% at 2 years).
This work highlights the challenge in understand-
ing the potential clinical value of a biomarker (10,19).
Important metrics, modiﬁed from an American Heart
Association Scientiﬁc Statement (10), including un-
ﬁnished work with pro-substance P, are outlined in
Table 1. The assay Ng et al. (18) used measures the
precursor of substance P, pro-tachykinin A. Whereas
pro-substance P is stochiometrically converted to
substance P, the rate of conversion may vary and the
correlation between pro-substance P and substance P
has not been demonstrated. Additionally, plasma
samples suffer signiﬁcant degradation in signal over
24 h, and certainly by 48 h (20), which has implica-
tions for the assay’s broad clinical applicability.
There is a major need to distill the vast information
in biomarkers with initial proof of concept, such as
pro-substance P, but then, translating that informa-
tion into clinical tools to guide and improve care is
the most challenging part of clinical risk marker
development. Although the work of Ng et al. (18) is a
ﬁrst step, it is a long journey.
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